Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Stephane Piat"


2 mentions found


An artificial heart by French manufacturer Carmat is seen during an interview with Reuters in Velizy, near Paris, January 11, 2021. Sources said Carmat, which had 24 million euros cash at mid-year, was looking to raise a total of around 100 million. Airbus said this week it had invested 50 million euros in Carmat but did not address whether it would spend more. It most recently invested 10 million euros in March 2022. Matra Defense paid a dividend of 207 million euros to Airbus in 2022, filings show.
Persons: Christian Hartmann, Jean, Luc Lagardere, Alain Carpentier, Carpentier, Stephane Piat, Emmanuel Macron, Thomas Toepfer, Piat, Samir Devani, Carmat, Tim Hepher, Michal Aleksandrowicz, Laura Lenkiewicz, Stephanie Hamel, Josephine Mason, Elaine Hardcastle Organizations: Reuters, REUTERS, Rights, Airbus, PARIS, Lagardere's Matra Defense, Carmat, Rx Securities, FDA, Zurich University, Matra Defense, Thomson Locations: Velizy, Paris, French, Carmat, United States, Lagardere, Taiwan
PARIS, Jan 4 (Reuters) - French healthcare and medical technology company CARMAT (ALCAR.PA) said on Wednesday that its Aeson artificial heart product would be implemented within the framework of a clinical study in France known as 'EFICAS'. "EFICAS is the largest study undertaken by CARMAT at this stage, and I am delighted that it will entirely take place in France, thus enabling our country's patients to benefit from our therapy. This is a crucial study, as it will eventually notably allow us to obtain Aeson’s reimbursement in France," said CARMAT chief executive Stéphane Piat in a statement. Reporting by Sudip Kar-Gupta; Editing by Christopher CushingOur Standards: The Thomson Reuters Trust Principles.
Total: 2